Emami Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8itz9gai8gaja0mfy4hy4oc4.pdf

Key Takeaways


Summer Season & Portfolio Performance

Mohan Goenka: "We haven't lost even 0.1% market share in the cooling oil. So, unfortunately, the season was bad, which you all are aware."

Channel Mix & Distribution

Mohan Goenka: "This year our focus has been primarily on expanding margins in modern trade and e-commerce."

Margins & Investment

Mohan Goenka: "We will be very careful. We will wait and watch how the winter pans out to be. If the winter is good, then we would definitely increase A&P by 1%. But overall, despite of that, we expect margins to increase by at least 200 basis points, 250 basis points."

Healthcare & Digital


International Business


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin expansionAt least 200–250 bps YoY expansionFull year FY24
Modern Trade and e-commerce growth15–20% growth from current ~20% contributionOngoing
Modern Trade and e-commerce mixReach 25–26% of salesNext 2–3 years
Male Grooming growthDouble-digit growthFrom Q2 FY24 onwards
International business growth~15% long-term growthLong-term
Healthcare growthDouble-digit growthOngoing
Kesh King growth~7–8% growthNext 2–3 years
Innovation contribution~3% of salesFull year FY24
Hospital transaction closureTransaction completedBy end of current month
A&P step-upIncrease A&P by 1%Conditional on a good winter season

Key Metrics

MetricQ1 FY24
Consolidated revenue~7% growth YoY
Domestic volume growth3%
Gross margin65.4%, expanded 240 bps YoY
EBITDA₹190 cr, +10% YoY; margin at 23%, expanded 60 bps YoY
Profit after tax₹138 cr, +87% YoY
Adjusted PAT₹161 cr, +17% YoY
EBITDA margin guidance (FY24)At least 27.5%, +200-250 bps YoY (per an analyst's math)
Pain Management growth13%
Healthcare range growth11%
Boro Plus range growth19%
Navratna range growth-8%
Dermicool growth9%
Kesh King growth2%
Male grooming range growthFlat
Modern Trade growth45%
E-commerce growth47%
Modern Trade and e-commerce saliency19.4% of domestic sales, +510 bps YoY
International business growth8% reported, 11% constant currency
International business growth ex-Egypt~20% constant currency
A&P spend growth11%
Depreciation and amortization₹46 cr (includes ₹16 cr Brillare write-off)
Innovation contribution~2.5% of revenue in Q1; FY24 expected ~3%
D2C/acquired companies (TMC, Brillare) contribution4-5% of sales in FY24
TMC and Brillare growth~27%
Pledge level33% currently; expected 18-20% post-hospital transaction
MAT credit balance~₹300 cr as of June 23
Summer portfolio contribution~41% of Q1 sales